{
  "meta": {
    "title": "Drug Interactions",
    "subtitle": "Kavalactones inhibit important liver enzymes: What you need to know about CYP450 interactions and safe combinations.",
    "category": "Safety",
    "breadcrumbs": {
      "home": "Home",
      "sicherheit": "Safety",
      "current": "Interactions"
    }
  },
  "toc": {
    "title": "Contents",
    "zusammenfassung": "Summary",
    "cyp450": "The CYP450 System",
    "welcheEnzyme": "Affected Enzymes",
    "klinischeBedeutung": "Clinical Significance",
    "hochrisiko": "High-Risk Combinations",
    "alkohol": "Alcohol",
    "benzodiazepine": "Benzodiazepines & Sleep Medications",
    "antipsychotika": "Antipsychotics",
    "antikoagulantien": "Anticoagulants",
    "moderatesRisiko": "Moderate Risk",
    "antidepressiva": "Antidepressants",
    "antikonvulsiva": "Anticonvulsants",
    "parkinson": "Parkinson's Medications",
    "hepatotoxisch": "Hepatotoxic Medications",
    "tabelle": "Interaction Table",
    "empfehlungen": "Practical Recommendations",
    "quellen": "Sources"
  },
  "navigation": {
    "continueTitle": "Continue in the Safety Chapter",
    "items": [
      {
        "title": "Overview",
        "href": "/de/sicherheit",
        "description": "Back to the Safety Overview"
      },
      {
        "title": "Liver Safety",
        "href": "/de/sicherheit/leber",
        "description": "Hepatotoxicity & the 2002 Ban"
      },
      {
        "title": "Contraindications",
        "href": "/de/sicherheit/kontraindikationen",
        "description": "When Kava should be avoided"
      },
      {
        "title": "Interaction Checker",
        "href": "/de/sicherheit/checker",
        "description": "Check your medications"
      }
    ]
  },
  "zusammenfassung": {
    "title": "Important Warning",
    "intro": "Kava has a <strong>high potential for drug interactions</strong> due to the inhibition of cytochrome P450 enzymes. Never combine Kava with:",
    "items": [
      {
        "name": "Alcohol",
        "text": "Increased sedation and liver toxicity"
      },
      {
        "name": "Benzodiazepines",
        "text": "Risk of respiratory depression"
      },
      {
        "name": "Antipsychotics",
        "text": "Increased sedation, movement disorders"
      },
      {
        "name": "Anticoagulants",
        "text": "Risk of bleeding"
      }
    ]
  },
  "cyp450": {
    "title": "The Cytochrome P450 System",
    "intro": "The cytochrome P450 system (CYP450) is a family of enzymes in the liver responsible for the metabolism of most medications. When a substance inhibits these enzymes, other substances are metabolized more slowly – their effects and side effects can therefore be amplified.",
    "importance": {
      "title": "Why is this important?",
      "text": "About <strong>70-80% of all medications</strong> are metabolized by CYP450 enzymes. When Kava inhibits these enzymes, the concentration of other medications in the blood can increase – sometimes to dangerous levels. This is especially true for medications with a <strong>narrow therapeutic window</strong>, where small changes in dosage can have significant effects."
    }
  },
  "enzyme": {
    "title": "Which enzymes are inhibited?",
    "intro": "Studies by Mathews et al. (2002) and other researchers have shown that Kavalactones inhibit several important CYP450 enzymes:",
    "headers": [
      "Enzyme",
      "Inhibition Strength",
      "Important Substrates (Examples)"
    ],
    "rows": [
      {
        "enzyme": "CYP1A2",
        "strength": "Strong",
        "substrates": "Caffeine, Theophylline, Clozapine, Olanzapine"
      },
      {
        "enzyme": "CYP2C9",
        "strength": "Strong",
        "substrates": "Warfarin, Phenytoin, NSAIDs (Ibuprofen)"
      },
      {
        "enzyme": "CYP2C19",
        "strength": "Moderate",
        "substrates": "Omeprazole, Diazepam, Clopidogrel"
      },
      {
        "enzyme": "CYP2D6",
        "strength": "Moderate",
        "substrates": "Codeine, Tramadol, many antidepressants"
      },
      {
        "enzyme": "CYP3A4",
        "strength": "Strong",
        "substrates": "Benzodiazepines, Statins, many antibiotics"
      }
    ]
  },
  "klinischeBedeutung": {
    "title": "Clinical Significance",
    "text": "A study by Russmann et al. (2005) showed that traditional aqueous Kava extracts also inhibit CYP1A2 in humans. The inhibition was dose-dependent and clinically relevant. This means that even traditionally prepared Kava can cause interactions.",
    "positive": {
      "title": "Positive Side Effect?",
      "text": "The CYP1A2 inhibition could theoretically provide a protective effect against certain environmental carcinogens that are activated by this enzyme. This could explain why Pacific populations have low cancer rates despite high Kava consumption."
    }
  },
  "hochrisiko": {
    "title": "High-Risk Combinations",
    "intro": "The following combinations should <strong>be avoided at all costs</strong>. They can lead to severe, potentially life-threatening side effects."
  },
  "alkohol": {
    "title": "Alcohol",
    "risk": "VERY HIGH",
    "intro": "The combination of Kava and alcohol is particularly dangerous for several reasons:",
    "points": [
      {
        "number": "1.",
        "label": "Synergistic Sedation",
        "text": "Both substances have a sedative effect on the CNS. The combined effect is stronger than the sum of the individual effects."
      },
      {
        "number": "2.",
        "label": "Additive Hepatotoxicity",
        "text": "Both substances are metabolized in the liver and can burden it. The combination significantly increases the risk of liver damage."
      },
      {
        "number": "3.",
        "label": "CYP Interaction",
        "text": "Alcohol also affects CYP enzymes, which can lead to unpredictable interactions."
      }
    ],
    "recommendation": "Recommendation: At least 24 hours between alcohol and Kava consumption."
  },
  "benzodiazepine": {
    "title": "Benzodiazepines & Sleep Medications",
    "risk": "VERY HIGH",
    "intro": "Benzodiazepines (Diazepam, Lorazepam, Alprazolam, etc.) and Z-Drugs (Zolpidem, Zopiclone) should never be combined with Kava:",
    "points": [
      {
        "label": "Increased Sedation",
        "text": "Both act on GABA receptors and enhance each other"
      },
      {
        "label": "Respiratory Depression",
        "text": "The combination can dangerously slow down breathing"
      },
      {
        "label": "CYP3A4 Inhibition",
        "text": "Kava slows the metabolism of benzodiazepines, prolonging their effect"
      }
    ],
    "caseReportLabel": "Case Report:",
    "caseReport": "Almeida & Grimsley (1996) reported on a 54-year-old man who fell into a semi-comatose state after combining Kava with Alprazolam."
  },
  "antipsychotika": {
    "title": "Antipsychotics",
    "risk": "HIGH",
    "intro": "Antipsychotics such as Haloperidol, Risperidone, Olanzapine, and Clozapine:",
    "points": [
      {
        "label": "Increased Sedation",
        "text": "Additive CNS depressant effect"
      },
      {
        "label": "Extrapyramidal Symptoms",
        "text": "Increased risk of movement disorders"
      },
      {
        "label": "CYP1A2/CYP2D6 Inhibition",
        "text": "Slowed metabolism, higher blood levels"
      }
    ]
  },
  "antikoagulantien": {
    "title": "Anticoagulants (Blood Thinners)",
    "risk": "HIGH",
    "intro": "Warfarin and other vitamin K antagonists:",
    "points": [
      {
        "label": "CYP2C9 Inhibition",
        "text": "Kava inhibits the enzyme that metabolizes Warfarin"
      },
      {
        "label": "Increased INR",
        "text": "Increased tendency to bleed"
      },
      {
        "label": "Risk of Bleeding",
        "text": "Can lead to dangerous internal bleeding"
      }
    ],
    "recommendation": "Kava is contraindicated when taking anticoagulants."
  },
  "moderatesRisiko": {
    "title": "Combinations with Moderate Risk",
    "intro": "The following combinations require caution and should only be undertaken after consulting a physician. A dosage adjustment may be necessary."
  },
  "antidepressiva": {
    "title": "Antidepressants",
    "risk": "MODERATE",
    "ssri": {
      "title": "SSRIs (Fluoxetine, Sertraline, Paroxetine, etc.):",
      "items": [
        "CYP2D6 inhibition may slow metabolism",
        "Theoretical risk of serotonin syndrome (low)",
        "Increased sedation possible"
      ]
    },
    "snri": {
      "title": "SNRIs (Venlafaxine, Duloxetine):",
      "items": [
        "Similar interactions as SSRIs",
        "CYP2D6 inhibition relevant for Venlafaxine"
      ]
    },
    "mao": {
      "title": "MAO Inhibitors:",
      "items": [
        "Kava weakly inhibits MAO-B",
        "Theoretical risk, but clinically poorly documented",
        "Caution with irreversible MAO inhibitors"
      ]
    }
  },
  "antikonvulsiva": {
    "title": "Anticonvulsants (Antiepileptics)",
    "risk": "MODERATE",
    "intro": "Phenytoin, Carbamazepine, Valproate, and other anticonvulsants:",
    "points": [
      {
        "label": "CYP Interactions",
        "text": "Altered blood levels possible"
      },
      {
        "label": "Increased Sedation",
        "text": "Additive CNS effect"
      },
      {
        "label": "Seizure Control",
        "text": "May be impaired"
      }
    ],
    "note": "In epilepsy, Kava should only be used under medical supervision."
  },
  "parkinson": {
    "title": "Parkinson's Medications",
    "risk": "MODERATE to HIGH",
    "intro": "Levodopa and dopamine agonists:",
    "points": [
      {
        "label": "Dopamine Antagonism",
        "text": "Kava may reduce the effect of Levodopa"
      },
      {
        "label": "Case Report",
        "text": "Worsening of Parkinson's symptoms documented under Kava"
      }
    ],
    "recommendation": "Kava is contraindicated in Parkinson's disease."
  },
  "hepatotoxisch": {
    "title": "Hepatotoxic Medications",
    "risk": "MODERATE",
    "intro": "Medications with known hepatotoxic potential:",
    "items": [
      {
        "name": "Paracetamol/Acetaminophen",
        "text": "Especially problematic at higher doses"
      },
      {
        "name": "Statins",
        "text": "Atorvastatin, Simvastatin, etc. (CYP3A4 substrates)"
      },
      {
        "name": "Methotrexate",
        "text": "Immunosuppressant with hepatotoxicity"
      },
      {
        "name": "Isoniazid",
        "text": "Tuberculosis medication"
      }
    ],
    "note": "Combining with hepatotoxic medications increases the risk of liver damage."
  },
  "tabelle": {
    "title": "Overview Table of Interactions",
    "headers": [
      "Substance Class",
      "Examples",
      "Risk",
      "Mechanism"
    ],
    "rows": [
      {
        "class": "Alcohol",
        "examples": "Ethanol",
        "risk": "VERY HIGH",
        "mechanism": "Synergistic sedation, hepatotoxicity"
      },
      {
        "class": "Benzodiazepines",
        "examples": "Diazepam, Lorazepam, Alprazolam",
        "risk": "VERY HIGH",
        "mechanism": "GABA enhancement, CYP3A4 inhibition"
      },
      {
        "class": "Antipsychotics",
        "examples": "Haloperidol, Olanzapine, Clozapine",
        "risk": "HIGH",
        "mechanism": "CYP1A2/2D6 inhibition, sedation"
      },
      {
        "class": "Anticoagulants",
        "examples": "Warfarin, Phenprocoumon",
        "risk": "HIGH",
        "mechanism": "CYP2C9 inhibition, bleeding risk"
      },
      {
        "class": "SSRIs",
        "examples": "Fluoxetine, Sertraline, Paroxetine",
        "risk": "MODERATE",
        "mechanism": "CYP2D6 inhibition"
      },
      {
        "class": "Anticonvulsants",
        "examples": "Phenytoin, Carbamazepine",
        "risk": "MODERATE",
        "mechanism": "CYP interactions, sedation"
      },
      {
        "class": "Parkinson's Medications",
        "examples": "Levodopa, Dopamine Agonists",
        "risk": "MODERATE",
        "mechanism": "Dopamine antagonism"
      },
      {
        "class": "Statins",
        "examples": "Atorvastatin, Simvastatin",
        "risk": "MODERATE",
        "mechanism": "CYP3A4 inhibition, hepatotoxicity"
      },
      {
        "class": "Opioids",
        "examples": "Codeine, Tramadol, Morphine",
        "risk": "MODERATE",
        "mechanism": "CYP2D6 inhibition, sedation"
      },
      {
        "class": "Caffeine",
        "examples": "Coffee, Energy Drinks",
        "risk": "LOW",
        "mechanism": "CYP1A2 inhibition (prolonged effect)"
      }
    ]
  },
  "empfehlungen": {
    "title": "Practical Recommendations",
    "checklistTitle": "Checklist Before Kava Consumption",
    "items": [
      {
        "number": "1.",
        "label": "Check Medication List",
        "text": "Review all current medications for interactions"
      },
      {
        "number": "2.",
        "label": "Consult a Doctor",
        "text": "Seek medical advice before Kava consumption if taking medications regularly"
      },
      {
        "number": "3.",
        "label": "Avoid Alcohol",
        "text": "Do not drink alcohol at least 24 hours before and after Kava consumption"
      },
      {
        "number": "4.",
        "label": "Dose Low",
        "text": "Start with a lower Kava dose when taking medications simultaneously"
      },
      {
        "number": "5.",
        "label": "Monitor Symptoms",
        "text": "Watch for unusual fatigue, dizziness, or other symptoms"
      }
    ],
    "professionalNote": {
      "title": "Note for Physicians and Pharmacists",
      "text": "In patients consuming Kava, a review of medications for CYP450 substrates should be conducted. Special caution is warranted for medications with a narrow therapeutic window. A dosage adjustment may be necessary."
    }
  },
  "quellen": {
    "title": "Sources",
    "items": [
      {
        "author": "Mathews J.M. et al. (2002):",
        "title": "Inhibition of Human Cytochrome P450 Activities by Kava Extract and Kavalactones.",
        "source": "Drug Metabolism and Disposition."
      },
      {
        "author": "Anke J., Ramzan I. (2004):",
        "title": "Pharmacokinetic and pharmacodynamic drug interactions with Kava.",
        "source": "Journal of Ethnopharmacology."
      },
      {
        "author": "Russmann S. et al. (2005):",
        "title": "Traditional Aqueous Kava Extracts Inhibit Cytochrome P450 1A2 in Humans.",
        "source": "Clinical Pharmacology & Therapeutics."
      },
      {
        "author": "Izzo A.A. (2005):",
        "title": "Potential for interaction of kava and St. John's wort with drugs.",
        "source": "Journal of Ethnopharmacology."
      },
      {
        "author": "Unger M. et al. (2002):",
        "title": "Inhibition of Cytochrome P450 3A4 by Extracts and Kavalactones of Piper methysticum.",
        "source": "Planta Medica."
      }
    ],
    "moreStudies": "A complete list of all cited studies can be found on our",
    "studiesLink": "Studies Page"
  }
}
